RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the variants of COVID19
The initiative is an innovative vaccine-focused research project that brings together the expertise of a number of European organisations and companies that work in vaccine design and manufacturing, clinical, trials and research, vaccine distribution and commercialisation, regulatory aspects, stakeholder involvement, trial and patient community perspective.
COVID-19 has been categorised by the WHO as a pandemic. Apart from it being a global health crisis some of the containment measures adopted by different countries have incurred inevitable socio-economic implications.
Participate in the clinical trial and helps to fulfil the purpose of the project: to offer a new tool to control the pandemic at short-medium and long term, and to manufacture and test the first recombinant protein-based vaccine to be authorised in Europe
Susana Garayoa sgarayoa@zabala.eu
Phone number: M (+32) 484 61 91 64
(Brussels)
Amaia Cabezón acabezon@zabala.es
Phone number: M (+34) 673 744 542
(Pamplona)
